| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Small Interfering | 67 | 2024 | 857 | 16.180 |
Why?
|
| RNA Interference | 28 | 2024 | 593 | 5.340 |
Why?
|
| Huntington Disease | 10 | 2024 | 146 | 4.430 |
Why?
|
| Huntingtin Protein | 13 | 2024 | 138 | 4.300 |
Why?
|
| Oligonucleotides | 13 | 2024 | 211 | 3.720 |
Why?
|
| Lipids | 8 | 2022 | 307 | 3.430 |
Why?
|
| Oligonucleotides, Antisense | 11 | 2024 | 134 | 2.650 |
Why?
|
| Gene Silencing | 21 | 2024 | 379 | 2.490 |
Why?
|
| Central Nervous System | 3 | 2024 | 192 | 2.150 |
Why?
|
| Animals | 60 | 2024 | 19729 | 1.980 |
Why?
|
| Mice | 40 | 2024 | 10311 | 1.940 |
Why?
|
| RNA, Messenger | 18 | 2024 | 1470 | 1.760 |
Why?
|
| Drug Delivery Systems | 6 | 2024 | 311 | 1.740 |
Why?
|
| Extracellular Vesicles | 3 | 2018 | 42 | 1.720 |
Why?
|
| Cholesterol | 6 | 2022 | 255 | 1.650 |
Why?
|
| Nucleic Acids | 3 | 2024 | 50 | 1.590 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 12 | 2020 | 253 | 1.510 |
Why?
|
| Neurons | 6 | 2019 | 861 | 1.420 |
Why?
|
| Fatty Acids | 3 | 2020 | 194 | 1.390 |
Why?
|
| Gene Transfer Techniques | 3 | 2020 | 307 | 1.240 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2024 | 33 | 1.220 |
Why?
|
| RNAi Therapeutics | 3 | 2021 | 12 | 1.160 |
Why?
|
| RNA | 9 | 2024 | 405 | 1.110 |
Why?
|
| HeLa Cells | 14 | 2019 | 528 | 1.100 |
Why?
|
| Exosomes | 2 | 2018 | 42 | 1.100 |
Why?
|
| Tissue Distribution | 8 | 2024 | 285 | 1.100 |
Why?
|
| Organophosphorus Compounds | 3 | 2023 | 32 | 1.040 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 1541 | 1.020 |
Why?
|
| Humans | 68 | 2024 | 60049 | 0.990 |
Why?
|
| Drug Design | 3 | 2024 | 144 | 0.980 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2024 | 136 | 0.890 |
Why?
|
| Species Specificity | 1 | 2024 | 335 | 0.880 |
Why?
|
| Apolipoproteins E | 4 | 2024 | 99 | 0.880 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 559 | 0.880 |
Why?
|
| MutS Homolog 3 Protein | 1 | 2023 | 4 | 0.860 |
Why?
|
| Liver | 12 | 2024 | 788 | 0.830 |
Why?
|
| Cell Nucleus | 2 | 2024 | 603 | 0.830 |
Why?
|
| RNA, Double-Stranded | 5 | 2023 | 108 | 0.810 |
Why?
|
| High-Throughput Screening Assays | 3 | 2017 | 73 | 0.790 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 55 | 0.780 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2022 | 21 | 0.780 |
Why?
|
| Organophosphonates | 2 | 2021 | 21 | 0.770 |
Why?
|
| DNA | 2 | 2023 | 793 | 0.760 |
Why?
|
| Genetic Therapy | 6 | 2023 | 744 | 0.740 |
Why?
|
| Skin Diseases | 1 | 2022 | 76 | 0.740 |
Why?
|
| Cells, Cultured | 9 | 2018 | 2099 | 0.740 |
Why?
|
| Myostatin | 1 | 2020 | 13 | 0.730 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2020 | 10 | 0.710 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2018 | 87 | 0.710 |
Why?
|
| Brain Neoplasms | 2 | 2024 | 306 | 0.650 |
Why?
|
| Kidney | 5 | 2019 | 395 | 0.650 |
Why?
|
| Nanoparticles | 2 | 2022 | 499 | 0.640 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 81 | 0.590 |
Why?
|
| Phosphorylcholine | 4 | 2019 | 41 | 0.580 |
Why?
|
| Vinyl Compounds | 1 | 2017 | 6 | 0.580 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 99 | 0.580 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2017 | 104 | 0.570 |
Why?
|
| Parenchymal Tissue | 1 | 2017 | 4 | 0.570 |
Why?
|
| Base Pair Mismatch | 3 | 2024 | 36 | 0.550 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 34 | 0.550 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 48 | 0.540 |
Why?
|
| Nucleic Acid Conformation | 9 | 2017 | 231 | 0.540 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 277 | 0.530 |
Why?
|
| Acetylgalactosamine | 3 | 2024 | 10 | 0.520 |
Why?
|
| Brain | 3 | 2024 | 1492 | 0.520 |
Why?
|
| Drug Discovery | 1 | 2017 | 92 | 0.520 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 104 | 0.510 |
Why?
|
| Guanabenz | 1 | 2015 | 3 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 182 | 0.510 |
Why?
|
| Endosomes | 1 | 2016 | 169 | 0.500 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 3207 | 0.500 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 193 | 0.480 |
Why?
|
| Disease Models, Animal | 8 | 2024 | 2080 | 0.470 |
Why?
|
| Transfection | 9 | 2008 | 676 | 0.460 |
Why?
|
| Prodrugs | 1 | 2014 | 32 | 0.460 |
Why?
|
| RNA, Catalytic | 5 | 2005 | 18 | 0.450 |
Why?
|
| MicroRNAs | 6 | 2024 | 622 | 0.450 |
Why?
|
| Base Sequence | 13 | 2018 | 1311 | 0.440 |
Why?
|
| Docosahexaenoic Acids | 3 | 2018 | 31 | 0.440 |
Why?
|
| Mutation | 6 | 2024 | 2464 | 0.430 |
Why?
|
| 3' Untranslated Regions | 3 | 2012 | 87 | 0.420 |
Why?
|
| Sheep | 2 | 2024 | 168 | 0.410 |
Why?
|
| Gene Editing | 3 | 2024 | 301 | 0.410 |
Why?
|
| Lung | 3 | 2023 | 841 | 0.410 |
Why?
|
| Cell Line | 10 | 2024 | 2015 | 0.410 |
Why?
|
| Corpus Striatum | 3 | 2023 | 96 | 0.400 |
Why?
|
| Response Elements | 1 | 2012 | 42 | 0.390 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 70 | 0.390 |
Why?
|
| Biological Transport | 3 | 2018 | 288 | 0.390 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 139 | 0.370 |
Why?
|
| RNA-Induced Silencing Complex | 4 | 2017 | 67 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 118 | 0.370 |
Why?
|
| Reperfusion Injury | 2 | 2022 | 51 | 0.350 |
Why?
|
| Female | 11 | 2021 | 31191 | 0.340 |
Why?
|
| Endocytosis | 3 | 2019 | 148 | 0.330 |
Why?
|
| Rats | 3 | 2024 | 1918 | 0.330 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 292 | 0.320 |
Why?
|
| Base Pairing | 2 | 2006 | 36 | 0.310 |
Why?
|
| Gene Expression Profiling | 4 | 2008 | 710 | 0.310 |
Why?
|
| Liver Transplantation | 2 | 2022 | 193 | 0.300 |
Why?
|
| Hepatocytes | 3 | 2019 | 194 | 0.300 |
Why?
|
| Neoplasms | 1 | 2018 | 1260 | 0.290 |
Why?
|
| Genome, Human | 2 | 2021 | 219 | 0.290 |
Why?
|
| Heart | 2 | 2020 | 276 | 0.290 |
Why?
|
| Melanoma | 4 | 2021 | 334 | 0.290 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 376 | 0.280 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 178 | 0.280 |
Why?
|
| Dystrophin | 2 | 2024 | 35 | 0.270 |
Why?
|
| Sequence Alignment | 2 | 2006 | 291 | 0.270 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 1380 | 0.260 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 34 | 0.260 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2024 | 42 | 0.260 |
Why?
|
| Interferons | 1 | 2006 | 63 | 0.250 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 194 | 0.250 |
Why?
|
| Gene Targeting | 2 | 2005 | 82 | 0.250 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 1225 | 0.240 |
Why?
|
| Thionucleotides | 4 | 2005 | 38 | 0.240 |
Why?
|
| Exons | 2 | 2023 | 193 | 0.240 |
Why?
|
| Endoribonucleases | 1 | 2005 | 53 | 0.240 |
Why?
|
| Diphosphates | 3 | 1993 | 10 | 0.240 |
Why?
|
| Antagomirs | 1 | 2024 | 5 | 0.230 |
Why?
|
| RNA Helicases | 1 | 2005 | 88 | 0.230 |
Why?
|
| Trinucleotide Repeats | 1 | 2024 | 20 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 454 | 0.230 |
Why?
|
| Amyloidogenic Proteins | 1 | 2024 | 11 | 0.230 |
Why?
|
| Codon, Nonsense | 1 | 2024 | 51 | 0.230 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 75 | 0.230 |
Why?
|
| Genomics | 1 | 2007 | 314 | 0.220 |
Why?
|
| Apolipoprotein E4 | 1 | 2024 | 35 | 0.220 |
Why?
|
| Alleles | 2 | 2022 | 422 | 0.220 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 18 | 0.220 |
Why?
|
| Genetic Engineering | 2 | 2004 | 112 | 0.220 |
Why?
|
| Amyloid | 1 | 2024 | 63 | 0.220 |
Why?
|
| Neostriatum | 1 | 2023 | 25 | 0.210 |
Why?
|
| Phenylalanine-tRNA Ligase | 2 | 1993 | 2 | 0.210 |
Why?
|
| RNA, Transfer, Phe | 2 | 1993 | 3 | 0.210 |
Why?
|
| Dogs | 1 | 2024 | 306 | 0.210 |
Why?
|
| Organ Preservation | 2 | 2022 | 18 | 0.210 |
Why?
|
| Gene Expression | 2 | 2016 | 807 | 0.210 |
Why?
|
| Sequence Analysis, RNA | 1 | 2004 | 155 | 0.210 |
Why?
|
| Perfusion | 2 | 2022 | 77 | 0.200 |
Why?
|
| Lysine-tRNA Ligase | 2 | 1992 | 3 | 0.200 |
Why?
|
| Molecular Sequence Data | 6 | 2008 | 1975 | 0.200 |
Why?
|
| Databases, Factual | 1 | 2006 | 849 | 0.200 |
Why?
|
| Glioblastoma | 1 | 2024 | 156 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2022 | 31 | 0.200 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 20 | 0.200 |
Why?
|
| Liposomes | 1 | 2022 | 100 | 0.200 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 37 | 0.200 |
Why?
|
| Cyclophilins | 2 | 2016 | 12 | 0.190 |
Why?
|
| Bulbo-Spinal Atrophy, X-Linked | 1 | 2021 | 2 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 259 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 28 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2005 | 98 | 0.190 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 42 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 48 | 0.180 |
Why?
|
| Cell Survival | 4 | 2006 | 558 | 0.180 |
Why?
|
| Vitiligo | 1 | 2023 | 120 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2022 | 176 | 0.180 |
Why?
|
| Cells | 1 | 2021 | 30 | 0.180 |
Why?
|
| Fibroblasts | 1 | 2022 | 370 | 0.180 |
Why?
|
| Muscular Diseases | 1 | 2020 | 47 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 113 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2023 | 317 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2022 | 548 | 0.170 |
Why?
|
| Synaptic Vesicles | 1 | 2019 | 26 | 0.170 |
Why?
|
| Thermodynamics | 4 | 2018 | 194 | 0.160 |
Why?
|
| Kinetics | 7 | 2005 | 737 | 0.160 |
Why?
|
| Receptors, LDL | 1 | 2019 | 33 | 0.160 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2019 | 16 | 0.160 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 46 | 0.160 |
Why?
|
| Carbocyanines | 1 | 2019 | 29 | 0.160 |
Why?
|
| Myocardium | 1 | 2020 | 263 | 0.160 |
Why?
|
| Blood Proteins | 1 | 2019 | 72 | 0.160 |
Why?
|
| Chitosan | 1 | 2019 | 83 | 0.160 |
Why?
|
| Umbilical Cord | 1 | 2018 | 9 | 0.160 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 26 | 0.160 |
Why?
|
| Mannitol | 1 | 2018 | 14 | 0.160 |
Why?
|
| Propylene Glycols | 1 | 2018 | 9 | 0.150 |
Why?
|
| RNA, Transfer | 2 | 2024 | 77 | 0.150 |
Why?
|
| Neuropeptides | 1 | 2019 | 82 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2024 | 251 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2020 | 206 | 0.150 |
Why?
|
| Aptamers, Nucleotide | 1 | 2018 | 18 | 0.150 |
Why?
|
| RNA Stability | 2 | 2017 | 94 | 0.150 |
Why?
|
| Carotid Arteries | 1 | 2018 | 59 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 155 | 0.150 |
Why?
|
| Molecular Structure | 1 | 2019 | 378 | 0.150 |
Why?
|
| Peptide Nucleic Acids | 1 | 2017 | 17 | 0.150 |
Why?
|
| Astrocytes | 1 | 2018 | 116 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2018 | 180 | 0.150 |
Why?
|
| Exoribonucleases | 1 | 2017 | 25 | 0.140 |
Why?
|
| Proteome | 1 | 2018 | 142 | 0.140 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 182 | 0.140 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 196 | 0.140 |
Why?
|
| Acylation | 6 | 1999 | 15 | 0.140 |
Why?
|
| Genetic Vectors | 3 | 2018 | 820 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 53 | 0.140 |
Why?
|
| Serine | 1 | 2017 | 83 | 0.140 |
Why?
|
| Drug Stability | 1 | 2017 | 138 | 0.140 |
Why?
|
| COS Cells | 1 | 2016 | 174 | 0.130 |
Why?
|
| Transferrin | 1 | 2016 | 67 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1297 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2017 | 860 | 0.130 |
Why?
|
| Poly U | 2 | 1992 | 2 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2017 | 1129 | 0.130 |
Why?
|
| Biotechnology | 1 | 2016 | 42 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 678 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 58 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1136 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 398 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 221 | 0.120 |
Why?
|
| Phenotype | 4 | 2021 | 1157 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 465 | 0.120 |
Why?
|
| Peptides | 1 | 2018 | 547 | 0.120 |
Why?
|
| Internet | 2 | 2008 | 463 | 0.110 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2013 | 31 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 1565 | 0.110 |
Why?
|
| Anticodon | 1 | 1992 | 11 | 0.110 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 1992 | 2 | 0.100 |
Why?
|
| Mice, Obese | 2 | 2024 | 79 | 0.100 |
Why?
|
| Retina | 1 | 2013 | 119 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2018 | 16 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 3 | 1999 | 529 | 0.100 |
Why?
|
| RNA, Bacterial | 1 | 1992 | 70 | 0.100 |
Why?
|
| Virus Replication | 2 | 2004 | 306 | 0.100 |
Why?
|
| Male | 5 | 2024 | 27914 | 0.100 |
Why?
|
| Escherichia coli | 2 | 1993 | 688 | 0.090 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2018 | 111 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 346 | 0.090 |
Why?
|
| HEK293 Cells | 2 | 2024 | 578 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2008 | 253 | 0.080 |
Why?
|
| Substrate Specificity | 2 | 2005 | 323 | 0.080 |
Why?
|
| Magnesium | 3 | 2004 | 58 | 0.080 |
Why?
|
| Catalysis | 3 | 2004 | 154 | 0.080 |
Why?
|
| Genetic Complementation Test | 1 | 2008 | 60 | 0.080 |
Why?
|
| Rabbits | 3 | 2013 | 331 | 0.080 |
Why?
|
| Time Factors | 5 | 2013 | 3610 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2022 | 417 | 0.070 |
Why?
|
| RNA, Antisense | 2 | 2007 | 49 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 647 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2008 | 59 | 0.070 |
Why?
|
| Plasmids | 3 | 2003 | 282 | 0.070 |
Why?
|
| Apoptosis | 4 | 2005 | 1040 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2008 | 132 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2007 | 19 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2005 | 184 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2007 | 101 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5258 | 0.070 |
Why?
|
| Cell Movement | 1 | 2008 | 425 | 0.070 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2006 | 6 | 0.070 |
Why?
|
| Silicon | 1 | 2006 | 22 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2008 | 376 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 330 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2004 | 265 | 0.060 |
Why?
|
| Manganese | 1 | 2005 | 24 | 0.060 |
Why?
|
| RNA, Transfer, Lys | 1 | 2004 | 1 | 0.060 |
Why?
|
| Ribonuclease III | 1 | 2005 | 81 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 848 | 0.060 |
Why?
|
| Gentamicins | 1 | 2024 | 23 | 0.060 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2005 | 77 | 0.060 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2024 | 11 | 0.060 |
Why?
|
| Diptera | 1 | 2004 | 3 | 0.060 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2004 | 19 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2024 | 39 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2019 | 2891 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 17 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2024 | 74 | 0.060 |
Why?
|
| Mice, Inbred mdx | 1 | 2023 | 18 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 291 | 0.060 |
Why?
|
| Janus Kinase 1 | 1 | 2023 | 10 | 0.060 |
Why?
|
| RNA, Plant | 1 | 2003 | 13 | 0.060 |
Why?
|
| Hepatic Stellate Cells | 1 | 2024 | 21 | 0.060 |
Why?
|
| Computational Biology | 1 | 2006 | 332 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2024 | 260 | 0.060 |
Why?
|
| Proteins | 3 | 2004 | 743 | 0.060 |
Why?
|
| Luciferases | 1 | 2004 | 109 | 0.050 |
Why?
|
| Collagen | 1 | 2024 | 119 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 108 | 0.050 |
Why?
|
| Software | 1 | 2007 | 373 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2004 | 113 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 168 | 0.050 |
Why?
|
| RNA Precursors | 1 | 2003 | 74 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2003 | 153 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1100 | 0.050 |
Why?
|
| Chemical Engineering | 1 | 2022 | 9 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2005 | 367 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 243 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 648 | 0.050 |
Why?
|
| Amines | 2 | 1992 | 30 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 160 | 0.050 |
Why?
|
| HIV-1 | 2 | 2004 | 709 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2024 | 295 | 0.050 |
Why?
|
| Trachea | 1 | 2022 | 92 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2005 | 353 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2023 | 221 | 0.050 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2021 | 12 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 801 | 0.050 |
Why?
|
| Fibrosis | 1 | 2021 | 152 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2003 | 140 | 0.050 |
Why?
|
| Dementia | 1 | 2024 | 252 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2021 | 195 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 304 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2003 | 771 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 144 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 91 | 0.040 |
Why?
|
| Drosophila | 1 | 2003 | 420 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 241 | 0.040 |
Why?
|
| Binding Sites | 2 | 2017 | 870 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 27 | 0.040 |
Why?
|
| Aspartate-tRNA Ligase | 1 | 1999 | 1 | 0.040 |
Why?
|
| RNA, Transfer, Asp | 1 | 1999 | 1 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 34 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 405 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1001 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 5 | 0.040 |
Why?
|
| Protein Binding | 1 | 2003 | 1561 | 0.040 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2018 | 3 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 484 | 0.040 |
Why?
|
| Models, Biological | 1 | 2003 | 1141 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2021 | 508 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 110 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2018 | 104 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2018 | 160 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 1128 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2017 | 133 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 91 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 622 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 325 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2018 | 492 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1109 | 0.030 |
Why?
|
| Caspases | 2 | 2005 | 164 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2005 | 274 | 0.030 |
Why?
|
| Genome, Viral | 2 | 2004 | 122 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 1190 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2013 | 49 | 0.030 |
Why?
|
| Eye Diseases | 1 | 2013 | 37 | 0.030 |
Why?
|
| Inorganic Pyrophosphatase | 1 | 1993 | 1 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 1993 | 11 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2004 | 305 | 0.030 |
Why?
|
| Yeasts | 1 | 1992 | 51 | 0.030 |
Why?
|
| Cattle | 1 | 1992 | 306 | 0.020 |
Why?
|
| Mitochondria | 2 | 2005 | 337 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5181 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4384 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 5949 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 28 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 85 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 88 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7593 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 177 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2007 | 40 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 258 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 13553 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2005 | 9 | 0.020 |
Why?
|
| Framycetin | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 25 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2005 | 21 | 0.020 |
Why?
|
| Thapsigargin | 1 | 2004 | 17 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2005 | 25 | 0.020 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 5 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 2004 | 21 | 0.020 |
Why?
|
| Taxoids | 1 | 2004 | 26 | 0.010 |
Why?
|
| Schistosoma | 1 | 2004 | 3 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2004 | 39 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 2004 | 18 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2005 | 137 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 119 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 104 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 15949 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 16500 | 0.010 |
Why?
|
| Catalase | 1 | 2004 | 21 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 16 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 525 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2004 | 38 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 942 | 0.010 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2004 | 3 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 127 | 0.010 |
Why?
|
| Clathrin | 1 | 2004 | 23 | 0.010 |
Why?
|
| Spodoptera | 1 | 2004 | 27 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2004 | 26 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 472 | 0.010 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2004 | 76 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 98 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 92 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 228 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 202 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 110 | 0.010 |
Why?
|
| Electroporation | 1 | 2003 | 32 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 428 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 148 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 293 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 183 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 187 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 443 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 498 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 443 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 638 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 379 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 316 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 597 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 710 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 1999 | 35 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 257 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 385 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 857 | 0.010 |
Why?
|